New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 24, 2012
10:25 EDTATML, WBS, SQNM, PROV, MRX, FLS, CCI, ATU, VECO, RBC, NICE, IEX, FCF, BAX, AKS, X, QCOR, MU, GRC, FNSROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AK Steel (AKS) downgraded to Sell from Neutral at Citigroup... Actuant (ATU) downgraded to Hold from Buy at Jefferies... Atmel (ATML) downgraded to Neutral from Buy at UBS... Baxter (BAX) downgraded to Hold from Buy at Deutsche Bank... Crown Castle (CCI) downgraded to Neutral from Outperform at Macquarie... Finisar (FNSR) downgraded to Market Perform from Outperform at Raymond James... First Commonwealth (FCF) downgraded to Market Perform at Keefe Bruyette... Flowserve (FLS) downgraded to Hold from Buy at Jefferies... Gorman-Rupp (GRC) downgraded to Underperform from Hold at Jefferies... IDEX Corp. (IEX) downgraded to Hold from Buy at Jefferies... Medicis (MRX) downgraded to Neutral from Positive at Susquehanna... Micron (MU) downgraded to Sector Perform from Outperform at Pacific Crest... NICE Systems (NICE) downgraded to Sector Perform from Outperform at RBC Capital... Providen (PROV) downgraded to Market Perform from Outperform at Raymond James... Questcor (QCOR) downgraded to Market Perform from Outperform at Leerink... Regal-Beloit (RBC) downgraded to Hold from Buy at Jefferies... Sequenom (SQNM) downgraded to Neutral from Overweight at Piper Jaffray... U.S. Steel (X) downgraded to Neutral from Buy at Citigroup... Veeco (VECO) downgraded to Sell from Neutral at Goldman... Webster Financial (WBS) downgraded to Underweight from Equal Weight at Morgan Stanley.
News For AKS;ATU;ATML;BAX;CCI;FNSR;FCF;FLS;GRC;IEX;MRX;MU;NICE;PROV;QCOR;RBC;SQNM;X;VECO;WBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
June 24, 2015
09:22 EDTMUMicron shares look 'egregiously inexpensive,' says Needham
Subscribe for More Information
07:43 EDTMUMicron June weekly volatility increases into Q3 and outlook
Micron June weekly option implied volatility is at 87, July is at 42, October is at 36; compared to its 52-range of 28 to 61, suggesting large near term price movement into its expected release of Q3 results on June 25.
07:30 EDTMUMicron fundamentals at inflection point, says UBS
UBS believes that Micron Technology fundamentals are at an inflection point and recommends buying the shares at current levels. The firm expects Q3 results and guidance can be better than feared and sees an earnings recovery, mostly influenced by smartphone fundamentals given significantly higher DRAM content. UBS maintained its $35 price target on Micron shares.
06:09 EDTMUOptions expected to be active
Options expected to be active: NFLX SYY MU MON NKE BBBY LEN NBG GREK
June 23, 2015
18:07 EDTBAXBaxter initiated with a Buy at Goldman
Subscribe for More Information
16:00 EDTMUOptions Update; June 23, 2015
iPath S&P 500 VIX Short-Term Futures down 46c to 17. Option volume leaders: AAPL FB AAPL T BAC MU BTU WMB AMZN TWTR BBRY
11:39 EDTMUStocks with call strike movement; TSLA MU
Subscribe for More Information
09:36 EDTATMLAtmel estimates lowered at Cleveland Research
Subscribe for More Information
09:36 EDTMUActive equity options trading on open
Subscribe for More Information
June 22, 2015
16:00 EDTMUOptions Update; June 22, 2015
iPath S&P 500 VIX Short-Term Futures down 78c to 17.45. Option volume leaders: AAPL FB BAC CHK WMB BABA TWTR MU AMBA TSLA JPM
12:33 EDTAKS, XSteel stocks lag market after AK Steel sees Q2 results hindered by imports
Subscribe for More Information
10:21 EDTFNSROptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTMUOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Akebia (AKBA) initiated with an Outperform at JMP Securities... Barracuda Networks (CUDA) initiated with a Buy at Summit Research... BioLineRx (BLRX) initiated with an Outperform at JMP Securities... Cabela's (CAB) initiated with an Outperform at Barrington... Chemours (CC) initiated with a Buy at Jefferies... Communications Sales & Leasing (CSAL) initiated with an Overweight at JPMorgan... E.W. Scripps (SSP) initiated with a Hold at Evercore ISI... EQT Corporation (EQT) reinstated with an Overweight at Barclays... EQT GP (EQGP) initiated with an Outperform at Credit Suisse... EQT Midstream Partners (EQM) initiated with a Buy at Deutsche Bank... Eagle Pharmaceuticals (EGRX) initiated with an Outperform at RBC Capital... Energen (EGN) initiated with a Buy at KLR Group... Ignyta (RXDX) initiated with an Overweight at Piper Jaffray... International Game (IGT) initiated with a Buy at BofA/Merrill... Leju (LEJU) initiated with an Overweight at Barclays... Micron (MU) initiated with an Outperform at Cowen... People's Utah Bancorp (PUB) initiated with a Buy at DA Davidson... SouFun (SFUN) initiated with an Overweight at Barclays... Turquoise Hill (TRQ) initiated with an Outperform at BMO Capital.
10:00 EDTMUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:14 EDTMUOn The Fly: Pre-market Movers
Subscribe for More Information
07:13 EDTRBCUBS to hold a conference
Subscribe for More Information
07:02 EDTMUMicron price target lowered to $33 from $37 at JPMorgan
Subscribe for More Information
06:32 EDTBAXKamada collaborates with Baxter on clinical trial with Alpha-1 antitrypsin
Kamada (KMDA) reports that the company has entered into a collaboration with Baxalta International, a wholly-owned subsidiary of Baxter (BAX) on a Phase 1/2 clinical trial of Kamada’s proprietary alpha-1 antitrypsin treatment for the prevention of lung transplant rejection. Under the agreement, Baxalta will collaborate in the development and funding of the study, which will be conducted in Israel. The study is expected to initiate in the first half of 2016, with more details on trial design to be provided at a later date. Kamada’s proprietary, highly-purified, liquid form of human AAT has shown positive interim results in a proof-of-concept Phase II study in Graft-versus-Host-Disease conducted at the Fred Hutchinson Cancer Research Center in cooperation with Baxalta. Based on those results, preclinical data published in Blood, and at the American Society of Hematology meeting, and a similar mechanism of action, the companies now plan to expand the AAT indication to the prevention of lung transplant rejection and may use this data to support clinical development worldwide. Baxalta has distribution rights to intravenous AAT for all indications in the U.S., Canada, Australia and New Zealand, while Kamada has rights in all other territories and all other formulations.
06:15 EDTMUMicron initiated with an Outperform at Cowen
Subscribe for More Information
05:31 EDTMUMicron downgraded to Sell from Neutral at Goldman
Goldman Sachs analyst Mark Delaney downgraded Micron Technology to Sell saying rising DRAM supply will lower selling prices and contract margins. Delaney expects DRAM prices to drop up to 30% over the next three quarters and cut his price target for shares to $19 from $27. The semiconductor provider closed Friday at $24.47.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use